OS Therapies to release 2.5-year overall survival data from Phase 2b OST-HER2 osteosarcoma trial at ASCO 2026

OS Therapies Incorporated

OS Therapies Incorporated

OSTX

0.00
  • OS Therapies flagged an upcoming release of 2.5-year overall survival results from its Phase 2b OST-HER2 osteosarcoma trial.
  • Data will be presented at the 2026 ASCO Annual Meeting running May 28 to June 2, 2026; results have not yet been disclosed.
  • The readout targets whether OST-HER2 can prevent or delay recurrence following full surgical removal of pulmonary metastatic osteosarcoma.
  • The company reiterated plans to seek a U.S. accelerated-approval BLA in the second half of 2026, with parallel filings planned abroad.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202605290720NEWSFILECNPR____20260529_299365_1) on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.